PUFA supplements
A technology of supplements and preparations, applied in allergic diseases, metabolic diseases, drug combinations, etc., can solve problems such as affecting dosage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1 to 3
[0056] Examples 1 to 3: Preparation of compositions containing PUFAs in balanced proportions
[0057] This example describes the blending of n-6 and n-3 oils so that they can be contained within a single capsule.
[0058] Compositions were prepared by mixing one n-6 PUFA-enriched oil with three different n-3 PUFA-enriched oils. The n-6 PUFA-enriched oil is derived from the fermentation of the filamentous fungus Mortierella alpina and contains about 40% ARA as the main fatty acid. Regarding n-3 PUFA rich oils, three different sources are: High EPA (above 45%) Low DHA (about 10%) fish oil (from Pronova, Norway, trade name EPAX TM , product number EPAx4510TG), high DHA (over 50%) low EPA (about 20%) fish oil (from Pronova, same brand, product number EPAx2050TG) and an oil derived from the fermentation of the unicellular alga Crypthecodinium cohnii containing 40% DHA as major fatty acids, but in fact lacks EPA (from Martek Corporation, Columbia, United States of America, trade ...
Embodiment 4
[0060] Example 4: Balanced supply of PUFAs to pregnant women in the first or third trimester
[0061] This example relates to a trial of supplementing pregnant women with ARA and DHA between the 6th and 15th weeks or between the 20th and 25th weeks of pregnancy until delivery (delivery). ARA source is a triglyceride oil containing 38% ARA, available from DSM / Gist-brocades, Delft, TheNetherlands under the trade name OPTIMAR TM . This is an oil produced by the fungus Mortierella alpina. For DHA, use food grade DHA-enriched fish oil or oil derived from algae, available from Martek Corporation under the trade name DHASCO TM .
[0062] Therefore, mothers who were supplemented with ARA and DHA during pregnancy were compared with a control group that did not receive supplementation, as measured by maternal fatty acid status at the time of delivery and the subsequent lactation period. Measurements included mother's red blood cell ARA and DHA values, umbilical artery and vein wal...
Embodiment 5
[0066] Example 5: Supplying Balanced PUFAs to the Elderly
[0067] Applicants recognize the need to improve the n-3 PUFA status of the population, especially the elderly, as diseases such as Parkinson's disease and Alzheimer's disease have been found to be associated with low PUFA status. This is thought to be due in part to an ineffective or deficient [Delta]6-desaturase. However, care is needed, especially in the elderly, as reduced ARA levels may exert negative effects on the immune system.
[0068] A formulation was prepared as in Example 1, containing n-3 and n-6 PUFAs in a DHA:ARA ratio of 2:1. Capsules were administered to healthy groups, elderly men and women (at least 65 years) at a dose of 1 g n-3 PUFA per day.
[0069]One month later, the PUFA status of the red blood cells of the subjects was assessed. In all cases, DHA levels were found to increase, while ARA levels remained constant, or in some cases showed a slight increase. Therefore, it is possible to i...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More